SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aster DM Healthcare delivers robust Q4 FY26 performance

… and Chairman, Aster DM Healthcare , said: Key Financial Highlights … Aster DM Healthcare for Q4 FY26: - … the merger of Aster DM Healthcare and Quality Care India … building a scaled and integrated healthcare platform. On a proforma basis …

India's healthcare expansion faces a critical talent crunch, says Alisha Moopen

Aster DM Healthcare is gearing up for a significant upgrade, targeting a capacity of 15,000 beds by the fiscal year 2029. With plans driven by both natural growth and an ambitious merger, the company is optimistic about a surge in revenue and enhanced profit margins.

Aster DM Healthcare eyes expansion as Alisha Moopen aims for India's largest clinical chain

Alisha Moopen is driving Aster DM Healthcare's major expansion across India. The company plans to add over 3,300 beds, aiming to become the nation's largest healthcare chain. Aster DM Healthcare currently operates around 40 hospitals nationwide. Moopen emphasizes building trust in a technology-driven world. Family-led organizations like Aster DM Healthcare invest with patience for long-term growth.

Nurses on strike in Kerala units return to work, operations in full capacity: Aster DM Healthcare

The proceedings continue to be pending with the High Court for a final settlement between the Kerala Pvt Hospital Association and United Nurses Association

Aster DM Healthcare expands 'Women & Children' facility at Aster Whitefield Hospital, Bengaluru

… of years of trusted healthcare service in Bengaluru. With … & Chairman, Aster DM Healthcare , said, "As demand … standing among the top three private healthcare providers in the state. Shares … of Aster DM Healthcare Limited was last trading …

Aster DM Healthcare Expands Whitefield Hospital Capacity, Invests ₹96 Cr

… 39;s commitment to advancing healthcare in Bengaluru, the company said …

Aster DM Healthcare invests Rs 96 crore to expand Whitefield hospital

The expansion comes as demand for specialised maternal and child healthcare continues to grow in Bengaluru and surrounding regions.

Aster DM Healthcare invests Rs 96 crore to expand Whitefield facility; capacity to increase to 539 beds

Aster DM Healthcare has invested Rs 96 crore to expand its women and children facility at Aster Whitefield Hospital in Bengaluru. The hospital's bed capacity will increase significantly. This expansion enhances specialized maternity and pediatric care. The initiative aims to improve maternal and child health outcomes in the region. Aster DM Healthcare continues to grow its presence in Bengaluru.

Brief Healthcare: Kailera Therapeutics (KLRA): Peeking at the IPO Prospectus of a Neurological Therapy Biotech and more

In this briefing: Kailera Therapeutics (KLRA): Peeking at the IPO Prospectus of a Neurological Therapy Biotech Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech CRDF: Colorectal Cancer KOL Event RADX: RAD 101 Phase IIb Interim Analysis Primer: Aster DM Healthcare Ltd (ASTERDM IN) - Apr 2026 1. Kailera Therapeutics (KLRA): Peeking at the IPO Prospectus of a Neurological Therapy Biotech Kailera Therapeutics (KLRA US) is a clinical-stage biotech developing next-generation obesity therapies using GLP-1–based and multi-receptor mechanisms to address a global chronic disease affecting over 1 billion people. Its candidate, ribupatide, is in Phase 3 trials showing significant weight loss potential, alongside a broader pipeline of oral and injectable GLP-1 and tri-agonist therapies targeting differentiated efficacy and tolerability. The company filed for an IPO on March 27th, backed by top underwriters and nearly $1B in funding, with experienced leadership. 2.

Brief Healthcare: CRDF: Colorectal Cancer KOL Event and more

In this briefing: CRDF: Colorectal Cancer KOL Event RADX: RAD 101 Phase IIb Interim Analysis Primer: Aster DM Healthcare Ltd (ASTERDM IN) - Apr 2026 Podcast EP338: How Thermo Fisher Scientific Helps Advanced Semiconductor Development Primer: Orum Therapeutics (475830 KS) - Apr 2026 1. CRDF: Colorectal Cancer KOL Event Zacks Small-Cap Research Note for Cardiff Oncology, Inc. (CRDF) 2. RADX: RAD 101 Phase IIb Interim Analysis Zacks Small-Cap Research Note for Radiopharm Theranostics Limited (RADX) 3. Primer: Aster DM Healthcare Ltd (ASTERDM IN) - Apr 2026 Strategic Repositioning to an India-Centric Model: Following the separation of its GCC business, Aster DM Healthcare is now sharply focused on the high-growth Indian healthcare market. This strategic shift is backed by a significant planned investment of approximately ₹4,000 crore to add over 4,000 beds, aiming to position the company as one of the top three hospital chains in India. Integrated Healthcare Ecosystem Driving Synergies: The company operates a diversified and integrated model encompassing hospitals, clinics, and pharmacies.

Aster DM Quality Care Ltd. engages in the provision of healthcare solutions. It operates through the following segments: Hospitals, Clinics, Retail Pharmacies, and Others. The Hospitals segment manages hospitals and in-house pharmacies at the hospitals. The Clinics segment consists of clinics and in-house pharmacies at the clinics. The Retail Pharmacies segment includes standalone retail pharmacies and optical outlets. The Others segment provides healthcare consultancy services and others. The company was founded by Mandayapurath Azad Moopen in 1987 and is headquartered in Dubai, the United Arab Emirates.

Aster DM Quality Care Ltd.

Aster DM Healthcare Extends Rally: SEBI Analyst Sees Breakout Potential After ICRA Upgrade

Equity

Neutral Sentiment

Aster DM Healthcare shares rose over 1% in early trade on Thursday, extending their gains after the company reported Tuesday that it had opened its new 264-bed hospital in Kasaragod, Kerala. The stock has rallied 11% in the last five trading sessions.&nbsp;The company has set up Aster MIMS Kasaragod, the eighth hospital in the state, at an investment of ₹190 crore and built over 2.1 lakh sq ft. The hospital houses 31 medical specialties and is designed to provide advanced and affordable care for residents across the region.The development comes as the Union Health Ministry rolls out a major revision of rates for about 2,000 medical procedures under the Central Government Health Services (CGHS), effective Oct. 13.&nbsp;The new system introduces tiered rates based on hospital accreditation and capacity, with higher payments for hospitals accredited by NABH and NABL, as well as those in super-specialty categories.ICRA Upgrade Underscores Aster’s Financial StrengthSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Ca_mayankchandel">Mayank Singh Chandel</a> said Aster DM Healthcare’s fundamentals have gained traction following the latest ICRA ratings upgrade on Oct.3.&nbsp;<stembedurl>https://stocktwits.com/Ca_mayankchandel/message/631602147</stembedurl>The credit agency raised Aster’s long-term rating to [ICRA]A+ from [ICRA]A and short-term rating to [ICRA]A1+ from [ICRA]A1, reflecting the company’s improving financial profile and operational scale.As per ICRA, Aster reported an 11.9% increase in revenue in FY25, backed by robust patient volumes, improved case mix and cost discipline. The company's operating profit margin increased to 18.7% in FY2025 and 19.2% in the first quarter of FY26, and the adjusted margin (excluding non-operating items) was even higher at 19.5% and 20%, respectively.Chandel noted that Aster’s balance sheet has strengthened considerably since the sale of its GCC business, which generated ₹7,767.7 crore and resulted in a gain of ₹5,148.1 crore in FY2025.&nbsp;The company used part of the proceeds to issue a special dividend of ₹5,894.3 crore, while still retaining ₹1,380.5 crore in cash and liquid investments as of March 31, 2025.He pointed out that the upgrade reflects not only solid earnings but also Aster’s growing presence across South India, particularly in Kerala, which currently accounts for about 53% of the company’s revenues.Merger And Expansion To Boost ScaleChandel said Aster’s ongoing merger with Quality Care India Ltd (QCIL), the operator of CARE Hospitals, KIMSHEALTH, and Evercare, could be a defining milestone for the company. Once completed, the merger would position Aster DM Quality Care among India’s top three hospital chains.He added that the combined entity is expected to benefit from greater geographical reach, shared backend systems, and strong cost synergies through joint procurement and vendor management.Aster currently operates 19 hospitals, 10 clinics, 203 pharmacies, and 259 labs in five Indian states. It is also in the process of an aggressive expansion plan and will add 2,600 new beds by FY29, with a ₹2,500-crore investment, of which ₹400 crore has been spent so far.Technical ViewOn the charts, Chandel noted that Aster has been in a strong uptrend, having hit a new all-time high in July before entering a sideways consolidation phase. He said the stock recently broke out of that range with high volumes, confirming a renewed wave of buying interest.He added that the broader healthcare sector is also consolidating near its peak, and if the sector itself breaks out, it could lend further upside momentum to Aster DM Healthcare.Trading CallChandel maintained a positive trading bias with a stop-loss at ₹640, saying the uptrend remains intact as long as the stock holds above that level.He summed up the setup with a message: “In the market, patience pays. Aster waited quietly for its moment, and when the signal turned green, it didn’t crawl—it sprinted.”What Is The Retail Mood?On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/ASTERDM.NSE">Aster’s stock</a> has risen 35.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s latest ICRA upgrade to [ICRA]A+ and the opening of a new 264-bed hospital in Kasaragod come as it accelerates its expansion plans and merger progress with Quality Care India.

Current Price	729.65
Prev Close	733.00
Open	735.90
Dividend Yield	N/A
50-Day Moving Average	715.49
Beta	N/A
Avg. Volume	879,963.23
PE Ratio	101.82

52-Week High	891.30
52-Week Low	519.10
Market Capitalization	631.18B
EPS (Annual)	7.53
Price to Book	8.22
Revenue Per Employee	2.07M

Feed

News

Sentiment

Fundamentals

Info

ASTERDM.NSE Fundamentals